M-A of randomized trials: Conservative oxygen therapy for critically ill patients.
Conservative oxygen therapy for critically ill patients: a meta-analysis of randomized controlled trials – Journal of Intensive Care
The post M-A of randomized trials: Conservative oxygen therapy for critically ill patients. appeared first on Links Medicus.
Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management.
Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management – European Respiratory Review
The post Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. appeared first on Links Medicus.
WHO reports progress in the fight against tobacco epidemic – Highlights threats posed by new nicotine and tobacco products.
News release: WHO reports progress in the fight against tobacco epidemic – World Health Organization Report: WHO report on the global tobacco epidemic 2021: New and Emerging Products – World Health Organization Commentary: While Global Tobacco Control Measures Improve, Electronic Cigarettes Evade Regulation in Many Countries – Health Policy Watch Commentary on Twitter (thread […]
The post WHO reports progress in the fight against tobacco epidemic – Highlights threats posed by new nicotine and tobacco products. appeared first on Links Medicus.
Household transmission of SARS-CoV-2 from children and adolescents.
Household Transmission of SARS-CoV-2 from Children and Adolescents – New England Journal of Medicine Related: Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in […]
The post Household transmission of SARS-CoV-2 from children and adolescents. appeared first on Links Medicus.
COVID-19 and mucormycosis superinfection: the perfect storm.
COVID-19 and mucormycosis superinfection: the perfect storm – Infection Related: ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries. The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested […]
The post COVID-19 and mucormycosis superinfection: the perfect storm. appeared first on Links Medicus.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2
Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet Related: WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products […]
The post Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. appeared first on Links Medicus.
CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness.
CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation Related: RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection. Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death. Phase 1/2 RCT: CoronaVac […]
The post CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. appeared first on Links Medicus.
[Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and
Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv Commentary on Twitter (thread – click for more) Two new results on vaccine effectiveness of #CoronaVac and #AstraZeneca in #Brazil w/ @otavio_ranzani @juliocroda @datcummings Albert Ko, Jason Andrews and othershttps://t.co/grIg1ydMK6https://t.co/fGmDsi7NdL […]
The post [Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and 71.4% against deaths. appeared first on Links Medicus.
[Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and
Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil – medRxiv Commentary on Twitter (thread – click for more) Two new results on vaccine effectiveness of #CoronaVac and #AstraZeneca in #Brazil w/ @otavio_ranzani @juliocroda @datcummings Albert Ko, Jason Andrews and othershttps://t.co/grIg1ydMK6https://t.co/fGmDsi7NdL 1/8 — Matt Hitchings (@MHitchingsEpi) July 23, […]
The post [Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and 93.6% against death. appeared first on Links Medicus.
Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose.
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose – JAMA Internal Medicine Commentaries: Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose – Massachusetts General Hospital No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP […]
The post Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose. appeared first on Links Medicus.